Q-omics provides the consensus-scored MDM2 profile across patient tissues and cancer cell-line models. MDM2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MDM2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MDM2 RNA expression shows 19,398 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where MDM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MDM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MDM2 survival associations across molecular data types. MDM2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MDM2 RNA expression–survival associations across cancer types. High MDM2 expression shows unfavorable associations in LGG, UVM and MESO, but favorable associations in UCEC, KIRC and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for MDM2 RNA expression.
This table summarizes MDM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MDM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MDM2 shows higher tumor expression in KIRC, KIRP, LIHC, STAD, BRCA and THCA. The KIRC box plot shows higher MDM2 RNA expression in tumor versus normal tissue (log2 FC = +0.994, t-test p < 0.001).
This table shows molecular features associated with MDM2 in patient tissues and cancer cell lines. In patient samples, MDM2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MDM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
